

Sergio Prieto-González

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5861674/publications.pdf>

Version: 2024-02-01

59
papers

1,532
citations

430874

18
h-index

315739

38
g-index

62
all docs

62
docs citations

62
times ranked

2077
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnosis and classification of polyarteritis nodosa. <i>Journal of Autoimmunity</i> , 2014, 48-49, 84-89.	6.5	189
2	Positron emission tomography assessment of large vessel inflammation in patients with newly diagnosed, biopsy-proven giant cell arteritis: a prospective, caseâ€“control study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1388-1392.	0.9	148
3	A Large-Scale Genetic Analysis Reveals a Strong Contribution of the HLA Class II Region to Giant Cell Arteritis Susceptibility. <i>American Journal of Human Genetics</i> , 2015, 96, 565-580.	6.2	144
4	Prospective long term follow-up of a cohort of patients with giant cell arteritis screened for aortic structural damage (aneurysm or dilatation). <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1826-1832.	0.9	103
5	Blocking interferon Î³ reduces expression of chemokines CXCL9, CXCL10 and CXCL11 and decreases macrophage infiltration in ex vivo cultured arteries from patients with giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1177-1186.	0.9	89
6	Effect of Glucocorticoid Treatment on Computed Tomography Angiography Detected Large-Vessel Inflammation in Giant-Cell Arteritis. A Prospective, Longitudinal Study. <i>Medicine (United States)</i> , 2015, 94, e486.	1.0	78
7	Endothelin-1 promotes vascular smooth muscle cell migration across the artery wall: a mechanism contributing to vascular remodelling and intimal hyperplasia in giant-cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1624-1634.	0.9	67
8	Clinical and genetic characterization of the autoinflammatory diseases diagnosed in an adult reference center. <i>Autoimmunity Reviews</i> , 2016, 15, 9-15.	5.8	62
9	Emerging PD-1 and PD-1L inhibitors-associated myopathy with a characteristic histopathological pattern. <i>Autoimmunity Reviews</i> , 2020, 19, 102455.	5.8	51
10	Dermatomyositis presenting with severe subcutaneous edema: Five additional cases and review of the literature. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 228-233.	3.4	50
11	Imaging in systemic vasculitis. <i>Current Opinion in Rheumatology</i> , 2015, 27, 53-62.	4.3	49
12	Trabecular bone score improves fracture risk assessment in glucocorticoid-induced osteoporosis. <i>Rheumatology</i> , 2020, 59, 1574-1580.	1.9	47
13	Prognostic Factors of Death in 151 Adults With Hemophagocytic Syndrome: Etiopathogenically Driven Analysis. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2018, 2, 267-276.	2.4	35
14	Expression and Function of IL12/23 Related Cytokine Subunits (p35, p40, and p19) in Giant-Cell Arteritis Lesions: Contribution of p40 to Th1- and Th17-Mediated Inflammatory Pathways. <i>Frontiers in Immunology</i> , 2018, 9, 809.	4.8	33
15	The Expanding Role of Imaging in Systemic Vasculitis. <i>Rheumatic Disease Clinics of North America</i> , 2016, 42, 733-751.	1.9	30
16	Biological treatments in giant cell arteritis & Takayasu arteritis. <i>European Journal of Internal Medicine</i> , 2018, 50, 12-19.	2.2	30
17	Impact of remdesivir according to the pre-admission symptom duration in patients with COVID-19. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 3296-3302.	3.0	30
18	Treatment with angiotensin II receptor blockers is associated with prolonged relapse-free survival, lower relapse rate, and corticosteroid-sparing effect in patients with giant cell arteritis. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 772-777.	3.4	28

#	ARTICLE	IF	CITATIONS
19	A multidisciplinary registry of patients with autoimmune and immune-mediated diseases with symptomatic COVID-19 from a single center. <i>Journal of Autoimmunity</i> , 2021, 117, 102580.	6.5	23
20	Whole-body MRI and pathological findings in adult patients with myopathies. <i>Skeletal Radiology</i> , 2019, 48, 653-676.	2.0	21
21	<i>Pneumocystis jirovecii</i> pneumonia prophylaxis in immunocompromised patients with systemic autoimmune diseases. <i>Medicina Clínica</i> , 2019, 152, 502-507.	0.6	19
22	Amoxicillin-induced acute aseptic meningitis. <i>Journal of Clinical Neuroscience</i> , 2011, 18, 443-444.	1.5	17
23	Rituximab in Refractory Chronic Spontaneous Urticaria: An Encouraging Therapeutic Approach. <i>Skin Pharmacology and Physiology</i> , 2018, 31, 184-187.	2.5	17
24	Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 274-283.	0.8	16
25	Advances in the Diagnosis of Large Vessel Vasculitis. <i>Rheumatic Disease Clinics of North America</i> , 2015, 41, 125-140.	1.9	15
26	Beta 2 -Microglobulin Deficiency Could Precipitate an Antiphospholipid Syndrome-Like Prothrombotic Situation in Patients With Coronavirus Disease 2019. <i>ACR Open Rheumatology</i> , 2021, 3, 267-276.	2.1	15
27	Impact of a systematic evaluation of connective tissue disease on diagnosis approach in patients with interstitial lung diseases. <i>Medicine (United States)</i> , 2020, 99, e18589.	1.0	14
28	The impact of SARS-CoV-2 coronavirus infection in patients with systemic lupus erythematosus from a single center in Catalonia. <i>Clinical Rheumatology</i> , 2021, 40, 2057-2063.	2.2	13
29	Response to mepolizumab according to disease manifestations in patients with eosinophilic granulomatosis with polyangiitis. <i>European Journal of Internal Medicine</i> , 2022, 95, 61-66.	2.2	12
30	Influence of MUC5B gene on antisynthetase syndrome. <i>Scientific Reports</i> , 2020, 10, 1415.	3.3	12
31	C-reactive protein cut-off for early tocilizumab and dexamethasone prescription in hospitalized patients with COVID-19. <i>Scientific Reports</i> , 2022, 12, 5250.	3.3	11
32	HLA association with the susceptibility to anti-synthetase syndrome. <i>Joint Bone Spine</i> , 2021, 88, 105115.	1.6	8
33	Prevalence of cardiovascular risk factors, the use of statins and of aspirin in Takayasu Arteritis. <i>Scientific Reports</i> , 2021, 11, 14404.	3.3	8
34	Clinico-pathological phenotypes of systemic sclerosis-associated myopathy: analysis of a large multicentre cohort. <i>Rheumatology</i> , 2023, 62, SI82-SI90.	1.9	8
35	Gastrointestinal Involvement in Dermatomyositis. <i>Diagnostics</i> , 2022, 12, 1200.	2.6	6
36	Vertebral fracture risk in glucocorticoid-induced osteoporosis: the role of hypogonadism and corticosteroid boluses. <i>RMD Open</i> , 2020, 6, e001355.	3.8	5

#	ARTICLE	IF	CITATIONS
37	Simultaneous presentation of granulomatosis with polyangiitis (GPA) and immunoglobulin G4-related disease (IgG4-RD). Leaving an open question: widening the spectrum of a single disease or real overlap?. <i>Modern Rheumatology Case Reports</i> , 2021, 5, 108-112.	0.7	4
38	Role of MUC1 rs4072037 polymorphism and serum KL-6 levels in patients with antisyndetase syndrome. <i>Scientific Reports</i> , 2021, 11, 22574.	3.3	4
39	Evaluation of Aortic Inflammation Using Computed Tomographic Angiography: Vasculitis, Atherosclerosis, or Both. <i>Journal of the American Geriatrics Society</i> , 2015, 63, 415-416.	2.6	3
40	Utilidad de las técnicas de imagen en la valoración de la arteritis de células gigantes. <i>Medicina Clínica</i> , 2019, 152, 495-501.	0.6	3
41	Successful Extracorporeal Membrane Oxygenation in a Patient With Fulminant Lupus Myocarditis. <i>Revista Española De Cardiología (English Ed)</i> , 2017, 70, 1013-1014.	0.6	2
42	FRIO487â€¦UTILITY OF TRABECULAR BONE SCORE(TBS) FOR FRACTURE RISK ASSESSMENT IN GLUCOCORTICOID-INDUCED OSTEOPOROSIS. , 2019, , .		2
43	Localised granulomatosis with polyangiitis in an older patient with rheumatoid arthritis. <i>Age and Ageing</i> , 2020, 49, 146-148.	1.6	2
44	Clinical Presentation and Outcome of COVID-19 in a Latin American Versus Spanish Population: Matched Case-Control Study. <i>Infectious Diseases and Therapy</i> , 2022, 11, 1243-1251.	4.0	2
45	Chronic Obstructive Pyelonephritis. <i>New England Journal of Medicine</i> , 2014, 371, 1332-1332.	27.0	1
46	Quick diagnosis units: predictors of time to diagnosis and costs. <i>Medicine (United States)</i> , 2020, 99, e21241.	1.0	1
47	An 80-year-old man with headache, orbital pain and elevated ESR: challenges in the diagnosis of a patient with suspected giant cell arteritis. <i>Rheumatology</i> , 2021, 60, iii12-iii14.	1.9	1
48	HIV-associated vasculitis. Part II: histologic and angiographic diagnostic reconfirmation after an uncontrolled HIV infection and fatal outcome. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 117, 151-152.	0.8	1
49	Type 1 autoimmune hepatitis in a patient with microscopic polyangiitis: challenges in diagnosis and treatment. <i>Medicina Clínica</i> , 2011, 136, 345-348.	0.6	0
50	Authorsâ€™ response to the eLetter by Moisevet al. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, e71-e71.	0.9	0
51	Granulomatosis eosinofílica con poliangiitis (Churg-Strauss) y derrame pericárdico grave. <i>Medicina Clínica</i> , 2017, 148, e53.	0.6	0
52	A very late presentation of polymyalgia rheumatica in a patient with giant cell arteritis: recurrence or casual association?. <i>Modern Rheumatology Case Reports</i> , 2019, 3, 130-133.	0.7	0
53	FRIO466â€¦RISK FACTORS ASSOCIATED WITH THE DEVELOPMENT OF FRACTURES IN GLUCOCORTICOID TREATED PATIENTS. THE ROLE OF HYPOGONADISM. , 2019, , .		0
54	AB0214â€¦MUSCLE INVOLVEMENT IN SYSTEMIC SCLEROSIS. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
55	La clasificaci3n de las vasculitis sist3micas: es momento de su renovaci3n. Medicina Cl3nica, 2019, 153, 391-393.	0.6	0
56	Occlusive vasculopathy in human immunodeficiency virus (HIV)-associated vasculitis: unusual clinical and imaging course. Clinical and Experimental Rheumatology, 2017, 35 Suppl 103, 185-188.	0.8	0
57	Thrombotic Microangiopathy: a Challenging Diagnosis Always. Israel Medical Association Journal, 2016, 18, 437-438.	0.1	0
58	Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies.. Clinical and Experimental Rheumatology, 2022, 40, 274-283.	0.8	0
59	MO241: Nets and Terminal Complement Pathway as Potential Biomarkers for Complement Overactivation Assessment in Anca-Associated Vasculitis. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0